OBJECTIVE: To measure the serum levels of neutrophils chemokine granulocyte chemotactic protein-2 (GCP-2) and interleukin-8 (IL-8) in Crohn's disease (CD) and ulcerative colitis (UC) patients and compare them with serum levels of growth-related oncogene (GRO-alpha). METHODS: Forty-two patients with inflammatory bowel disease (24 CD and 18 UC) and 38 matched healthy subjects were recruited. Their serum GCP-2, IL-8 and GRO-alpha were measured by a specific enzyme immunoassay kit. RESULTS: The serum levels of GCP-2 were significantly higher in the CD than the UC patients but lower than in the healthy subjects. The GCP-2 in the UC patients were significantly lower than in the healthy subjects. The GRO-alpha levels were significantly higher in the IBD patients than in the healthy subjects. The IL-8 levels were under the detectable limit in both the IBD and the healthy subjects. CONCLUSION: In this group of patients, GCP-2 did not participate in the inflammatory response in IBD. GRO-alpha could be an important factor that enhances the inflammatory state in IBD.
OBJECTIVE: To measure the serum levels of neutrophils chemokine granulocyte chemotactic protein-2 (GCP-2) and interleukin-8 (IL-8) in Crohn's disease (CD) and ulcerative colitis (UC) patients and compare them with serum levels of growth-related oncogene (GRO-alpha). METHODS: Forty-two patients with inflammatory bowel disease (24 CD and 18 UC) and 38 matched healthy subjects were recruited. Their serum GCP-2, IL-8 and GRO-alpha were measured by a specific enzyme immunoassay kit. RESULTS: The serum levels of GCP-2 were significantly higher in the CD than the UC patients but lower than in the healthy subjects. The GCP-2 in the UC patients were significantly lower than in the healthy subjects. The GRO-alpha levels were significantly higher in the IBD patients than in the healthy subjects. The IL-8 levels were under the detectable limit in both the IBD and the healthy subjects. CONCLUSION: In this group of patients, GCP-2 did not participate in the inflammatory response in IBD. GRO-alpha could be an important factor that enhances the inflammatory state in IBD.
Authors: Jan Korbecki; Iwona Szatkowska; Patrycja Kupnicka; Wojciech Żwierełło; Katarzyna Barczak; Iwona Poziomkowska-Gęsicka; Jerzy Wójcik; Dariusz Chlubek; Irena Baranowska-Bosiacka Journal: Int J Mol Sci Date: 2022-06-28 Impact factor: 6.208
Authors: Gabrielle Boucher; Alexandre Paradis; Geneviève Chabot-Roy; Lise Coderre; Erin E Hillhouse; Alain Bitton; Christine Des Rosiers; Megan K Levings; L Philip Schumm; Mark Lazarev; Steve R Brant; Richard Duerr; Dermot McGovern; Mark S Silverberg; Judy Cho; Sylvie Lesage; John D Rioux Journal: Inflamm Bowel Dis Date: 2022-01-05 Impact factor: 7.290